Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients who receive cytokine treatments such as IL-2 or IFNγ as part of their treatment for hepatitis or cancer often develop depressive symptoms.
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
The introduction (section C; page unavailable) says that treatment with proinflammatory agents induces depressive symptoms, and the References list a study of interferon-α treatment in patients with malignant melanoma. Our copy does not substantiate the claim’s specific examples of IL-2 or IFNγ, its hepatitis setting, or the assertion that symptoms develop often. (LLM, conf=0.85)
Experimental — accuracy not yet measuredKohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects.
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
The Subanalyses section (page not available in our copy) reports higher antidepressant response with celecoxib add-on versus placebo (odds ratio 6.59), approximately the quoted sevenfold figure, though this is an odds ratio rather than a probability ratio. The Adverse Effects section says no increased gastrointestinal or cardiovascular risks were observed, but cautions that adverse effects were not reported by every study and treatment lasted only 6–12 weeks. The claim omits those limits on the safety finding. (LLM, conf=0.85)
Experimental — accuracy not yet measuredBlockade of cytokines such as TNF or of inflammatory signalling pathway components such as cyclooxygenase 2 reduces depressive symptoms in patients with medical illnesses including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder.
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
The Antidepressant Effects section reports improved depression or depressive symptoms with cytokine inhibitors in patients with psoriasis, and the Conclusions report improved antidepressant outcomes with add-on celecoxib. The copy does not establish the claimed reductions in patients with rheumatoid arthritis or cancer. It also qualifies the cytokine-inhibitor evidence: few trials were available, and the meta-analysis found no significant benefit over placebo. (LLM, conf=0.88)
Experimental — accuracy not yet measuredAnti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients with increased peripheral inflammation, such as those with osteoarthritis or psoriasis and depression with increased inflammatory markers.
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
The Perspectives section reports better responses among depressed patients with elevated inflammatory markers and among patients with depressive symptoms plus pain-related or inflammatory disorders. The Conclusions call for identifying subgroups that may benefit more, but do not establish that anti-inflammatory agents are effective *only* in those subgroups. The paper includes osteoarthritis and psoriasis trials, although it does not establish elevated peripheral markers in every patient with those conditions. (LLM, conf=0.86)
Experimental — accuracy not yet measuredDepressive symptoms are more frequent in patients with conditions involving inflammation and can be reversed through the use of anti-inflammatory drugs.
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
Meta-analytic evidence indicates anti-inflammatory treatments can effectively treat depression.
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms.
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
Anti-inflammatory treatments reduce depressive symptoms in humans.
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · see citing works
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395 · see citing works
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · see citing works
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · see citing works
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560 · see citing works
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · see citing works
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766 · see citing works
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,262 · see citing works
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766 · see citing works
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181 · see citing works
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · see citing works
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794 · see citing works
Bias in clinical intervention research.
Gluud, L. L. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj069 · Cited by 636 · see citing works
Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study
Benros, M. E., Waltoft, B. L., Nordentoft, M., Østergaard, S. D., Eaton, W. W., Krogh, J., & Mortensen, P. B. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1111 · Cited by 572 · see citing works
Self-citationAkhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397 · see citing works
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O. M., Drexhage, H. A., McNeil, J. J., Moylan, S., O'Neil, A. E., Davey, C. G., Sanna, L., & Maes, M. H. J. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 392 · see citing works
Appleton, K. M., Rogers, P. J., & Ness, A. R. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28313 · Cited by 353 · see citing works
Abbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 344 · see citing works
Olsen, A. S., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M. G., Selmer, C., Lamberts, M., Olesen, J., Køber, L., Hansen, P. R., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004671 · Cited by 334 · see citing works
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298 · see citing works
Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104836108 · Cited by 291 · see citing works
PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02535.x · Cited by 253 · see citing works
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229 · see citing works
Langley, R. G. B., Feldman, S. R., Han, C., Schenkel, B., Szapary, P. O., Hsu, M.-C., Ortonne, J. P., Gordon, K. B., & Kimball, A. B. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.014 · Cited by 218 · see citing works
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212 · see citing works
de Abajo, F. J., & García‐Rodríguez, L. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.7.795 · Cited by 206 · see citing works
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., & Correll, C. U. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt070 · Cited by 204 · see citing works
Tomás-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A., & Venero, J. L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.010 · Cited by 203 · see citing works
Menter, A., Augustin, M., Signorovitch, J., Yu, A. P., Wu, E. Q., Gupta, S. R., Bao, Y., & Mulani, P. M. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.07.022 · Cited by 197 · see citing works
Nonsteroidal Anti-Inflammatory Drugs in Schizophrenia
Sommer, I. E., de Witte, L. D., Begemann, M., & Kahn, R. S. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06823 · Cited by 182 · see citing works
Na, K., Lee, K. J., Lee, J. S., Cho, Y. S., & Jung, H. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.006 · Cited by 178 · see citing works
Fond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 172 · see citing works
Solomon, D. H., Avorn, J., Stürmer, T., Glynn, R. J., Mogun, H., & Schneeweiß, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21887 · Cited by 172 · see citing works
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153 · see citing works
Karson, A., Demirtaş, T., Bayramgürler, D., Balcı, F., & Utkan, T. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12037 · Cited by 143 · see citing works
Otte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K., & Kellner, M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.10.006 · Cited by 129 · see citing works
Ertenli, İ., Ozer, S., Kiraz, S., Apras, S., Akdoğan, A., Karadağ, Ö., Çalgünerı, M., & Kalyoncu, U. (2010) · Rheumatology International · doi:10.1007/s00296-010-1616-x · Cited by 129 · see citing works
Dexamethasone for the treatment of depression: a randomized, placebo- controlled, double-blind trial
Arana, G. W., Santos, A. B., Laraia, M. T., McLeod-Bryant, S., Beale, M. D., Rames, L. J., Roberts, J. M., Dias, J. K., & Molloy, M. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.265 · Cited by 127 · see citing works
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116 · see citing works
DeBattista, C., Posener, J. A., Kalehzan, B. M., & Schatzberg, A. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1334 · Cited by 113 · see citing works
Toussi, S. S., Pan, N., Walters, H. M., & Walsh, T. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit489 · Cited by 113 · see citing works
Wium‐Andersen, M. K., Ørsted, D. D., & Nordestgaard, B. G. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.009 · Cited by 107 · see citing works
NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis
Iyengar, R. L., Gandhi, S., Aneja, A., Thorpe, K. E., Razzouk, L., Greenberg, J., Mosovich, S., & Farkouh, M. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.037 · Cited by 106 · see citing works
Self-citationFields, C., Drye, L., Vaidya, V., & Lyketsos, C. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318227f4da · Cited by 96 · see citing works
Gallagher, P., Castro, V. M., D, M. F. M., Weilburg, J. B., Murphy, S. N., Gainer, V. S., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., Smoller, J. W., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11091325 · Cited by 79 · see citing works
The impact of statins on psychological wellbeing: a systematic review and meta-analysis
O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L. J., Pasco, J. A., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-154 · Cited by 78 · see citing works
Johansson, D., Falk, A., Marcus, M. M., & Svensson, T. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.003 · Cited by 60 · see citing works
Abolfazli, R., Hosseini, M., Ghanizadeh, A. J., Ghaleiha, A., Tabrizi, M. H., Raznahan, M., Golalizadeh, M., & Akhondzadeh, S. (2011) · Depression and Anxiety · doi:10.1002/da.20801 · Cited by 60 · see citing works
Collantes‐Estévez, E., & Fernández, C. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001938 · Cited by 52 · see citing works
Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder
Uher, R., Carver, S., Power, R. A., Mors, O., Maier, W., Rietschel, M., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291712000190 · Cited by 45 · see citing works
Self-citationFriebe, A., Horn, M., Schmidt, F., Janssen, G., Schmid-Wendtner, M.-H., Volkenandt, M., Hauschild, A., Goldsmith, C. H., & Schaefer, M. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70738-6 · Cited by 39 · see citing works
(2000) · Time to knit · doi:10.1016/s0084-3970(09)79072-3 · Cited by 18 · see citing works
Depression, Pain, and Comorbid Medical Conditions
Manning, J. S., & Jackson, W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12049vs3c · Cited by 12 · see citing works
Sommer, I. E., de Witte, L. D., Begemann, M., & Kahn, R. S. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70276-1 · Cited by 11 · see citing works
Otte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K., & Kellner, M. B. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1240192 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942 · see citing works
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269 · see citing works
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683 · see citing works
Kandola, A., Ashdown-Franks, G., Hendrikse, J., Sabiston, C. M., & Stubbs, B. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.040 · Cited by 1,309 · see citing works
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129 · see citing works
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073 · see citing works
Depression as a Microglial Disease
Yirmiya, R., Rimmerman, N., & Reshef, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.001 · Cited by 944 · see citing works
Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.02.010 · Cited by 937 · see citing works
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844 · see citing works
Peng, Y., Ao, M., BaoHua, D., Jiang, Y., Yu, L., Chen, Z., Hu, C.-J., & Xu, R. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 885 · see citing works
Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019) · Psychological Medicine · doi:10.1017/s0033291719001454 · Cited by 774 · see citing works
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659 · see citing works
The Role of Inflammation in Depression and Fatigue
Lee, C.-H., & Giuliani, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01696 · Cited by 640 · see citing works
Neuroimmune mechanisms of depression
Hodes, G. E., Kana, V., Menard, C., Merad, M., & Russo, S. J. (2015) · Nature Neuroscience · doi:10.1038/nn.4113 · Cited by 585 · see citing works
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592 · see citing works
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593 · see citing works
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566 · see citing works
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
Wang, H., He, Y., Sun, Z., Ren, S., Liu, M., Wang, G., & Yang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02492-0 · Cited by 591 · see citing works
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578 · see citing works
“IDO enzyme inhibitors QUIN (138) Overstimulates the NMDA receptor resulting in glutamatergic excitotoxicity GSK-3β inhibitors COX-2 (155) COX-2 increases PGE-2 resulting in glutamatergic excitability, stimulation of CRF, and the release of pro-inflammatory cytokines COX-2 inhibitors Proteoglycans (152) Reactive astroc…”
BackgroundInfluentialInflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516 · see citing works
Self-citationMicroglial regional heterogeneity and its role in the brain
Tan, Y.-L., Yuan, Y., & Tian, L. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0609-8 · Cited by 571 · see citing works
Inflammation in psychiatric disorders: what comes first?
Bauer, M. E., & Teixeira, A. L. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13712 · Cited by 500 · see citing works
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 455 · see citing works
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 453 · see citing works
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432 · see citing works
Self-citationDepression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression
Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.014 · Cited by 433 · see citing works
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 432 · see citing works
Rheumatoid arthritis and depression: an inflammatory perspective
Nerurkar, L., Siebert, S., McInnes, I. B., & Cavanagh, J. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30255-4 · Cited by 417 · see citing works
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415 · see citing works
Inflammation and post‐traumatic stress disorder
Hori, H., & Kim, Y. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12820 · Cited by 416 · see citing works
Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?
Danese, A., & J Lewis, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.198 · Cited by 393 · see citing works
Wang, A. K., & Miller, B. J. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx035 · Cited by 389 · see citing works
Immune and neuroendocrine mechanisms of stress vulnerability and resilience
Ménard, C., Pfau, M. L., Hodes, G. E., & Russo, S. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.90 · Cited by 374 · see citing works
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M. H. J., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 379 · see citing works
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348 · see citing works
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety
Bekhbat, M., & Neigh, G. N. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.006 · Cited by 359 · see citing works
Beyond a neurotransmitter: The role of serotonin in inflammation and immunity
Wu, H., Denna, T., Storkersen, J., & Gerriets, V. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.015 · Cited by 348 · see citing works
Neurobiology of Resilience: Interface Between Mind and Body
Cathomas, F., Murrough, J. W., Nestler, E. J., Han, M.-H., & Russo, S. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.011 · Cited by 296 · see citing works
Iob, E., Kirschbaum, C., & Steptoe, A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0501-6 · Cited by 305 · see citing works
Hidden wounds? inflammatory links between childhood trauma and psychopathology
Danese, A., & Baldwin, J. R. (2017) · Annual Review of Psychology · doi:10.1146/annurev-psych-010416-044208 · Cited by 286 · see citing works
Evaluation of various estimators for standardized mean difference in meta‐analysis
Lin, L., & Aloe, A. M. (2021) · Statistics in Medicine · doi:10.1002/sim.8781 · Cited by 297 · see citing works
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279 · see citing works
Köhler-Forsberg, O., Buttenschøn, H. N., Tansey, K. E., Maier, W., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.020 · Cited by 283 · see citing works
Self-citationCalipari, E. S., Godino, A., Peck, E. G., Salery, M., Mervosh, N. L., Landry, J. A., Russo, S. J., Hurd, Y. L., Nestler, E. J., & Kiraly, D. D. (2017) · Nature Communications · doi:10.1038/s41467-017-01881-x · Cited by 278 · see citing works
The microbiome, immunity, and schizophrenia and bipolar disorder.
Dickerson, F., Severance, E., & Yolken, R. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.010 · Cited by 268 · see citing works
Rapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B. L., Cardoos, A., Walker, R., & Mischoulon, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.22 · Cited by 271 · see citing works
Kappelmann, N., Arloth, J., Georgakis, M. K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G. M., & Binder, E. B. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3436 · Cited by 262 · see citing works
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258 · see citing works
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235 · see citing works
Nettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00948-6 · Cited by 235 · see citing works
Microbiome, inflammation, epigenetic alterations, and mental diseases
Alam, R., Abdolmaleky, H. M., & Zhou, J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32567 · Cited by 240 · see citing works
Milaneschi, Y., Lamers, F., Peyrot, W. J., Baune, B. T., Breen, G., Dehghan, A., Forstner, A. J., Grabe, H. J., Homuth, G., Kan, C., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3016 · Cited by 233 · see citing works
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233 · see citing works
Orlovska‐Waast, S., Köhler‐Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, D., Krogh, J., & Benros, M. E. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0220-4 · Cited by 233 · see citing works
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
The molecular and cellular mechanisms of depression: a focus on reward circuitry
Fox, M. E., & Lobo, M. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0415-3 · Cited by 232 · see citing works
Pu, J., Liu, Y., Zhang, H., Tian, L., Gui, S., Yu, Y., Chen, X., Chen, Y., Yang, L., Ran, Y., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0645-4 · Cited by 231 · see citing works
Lamers, F., Milaneschi, Y., Smit, J. H., Schoevers, R. A., Wittenberg, G. M., & Penninx, B. W. J. H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.020 · Cited by 219 · see citing works
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212 · see citing works
Syed, S. A., Beurel, E., Loewenstein, D., Lowell, J. A., Craighead, W. E., Dunlop, B. W., Mayberg, H. S., Dhabhar, F. S., Dietrich, W. D., Keane, R. W., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.001 · Cited by 212 · see citing works
NLRP1 inflammasome contributes to chronic stress-induced depressive-like behaviors in mice
Song, A., Gao, B., Fan, J.-J., Zhu, Y., Zhou, J., Wang, Y., Xu, L.-Z., & Wu, W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01848-8 · Cited by 208 · see citing works
Szymkowicz, S. M., Gerlach, A., Homiack, D., & Taylor, W. D. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02464-9 · Cited by 212 · see citing works
Rosenblat, J. D., Kakar, R., Berk, M., Kessing, L. V., Vinberg, M., Baune, B. T., Mansur, R. B., Brietzke, E., Goldstein, B. I., & McIntyre, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12373 · Cited by 199 · see citing works
The interplay between stress, inflammation, and emotional attention: relevance for depression
Maydych, V. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00384 · Cited by 193 · see citing works
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197 · see citing works
Immunopsychiatry: important facts
Khandaker, G. M., Dantzer, R., & Jones, P. B. (2017) · Psychological Medicine · doi:10.1017/s0033291717000745 · Cited by 200 · see citing works
Depression and diabetes: treatment and health-care delivery
Petrak, F., Baumeister, H., Skinner, T. C., Brown, A. D. H., & Holt, R. I. G. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00045-5 · Cited by 193 · see citing works
Metabolic and inflammatory markers: associations with individual depressive symptoms
Lamers, F., Milaneschi, Y., de Jonge, P., Giltay, E. J., & Penninx, B. W. J. H. (2017) · Psychological Medicine · doi:10.1017/s0033291717002483 · Cited by 197 · see citing works
Hou, R., Garner, M., Holmes, C., Osmond, C., Teeling, J., Lau, L., & Baldwin, D. S. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.021 · Cited by 191 · see citing works
Examining the role of neuroinflammation in major depression
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.009 · Cited by 191 · see citing works
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184 · see citing works
Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression
Lynall, M.-E., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W. C., Cowen, P., Harrison, N. A., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.11.017 · Cited by 187 · see citing works
van Dooren, F. E. P., Schram, M. T., Schalkwijk, C. G., Stehouwer, C. D. A., Henry, R. M. A., Dagnelie, P. C., Schaper, N. C., Kallen, C., Koster, A., Sep, S. J. S., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.004 · Cited by 187 · see citing works
Wittenberg, G. M., Stylianou, A., Zhang, Y., Sun, Y., Gupta, A., Jagannatha, P. S., Wang, D., Hsu, B. L., Curran, M. E., Khan, S. A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0471-8 · Cited by 188 · see citing works
Kiraly, D. D., Horn, S. R. G.-V., Dam, N. T. V., Costi, S., Kirshenbaum, J. S., Kim‐Schulze, S., Patel, M., Hodes, G. E., Russo, S. J., Mérad, M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.31 · Cited by 188 · see citing works
Wang, L., Wang, R., Liu, L., Qiao, D., Baldwin, D. S., & Hou, R. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.02.021 · Cited by 192 · see citing works
Rong, H., Xie, X., Zhao, J., Lai, W., Wang, M., Xu, D., Liu, Y., Guo, Y., Xu, S., Deng, W.-F., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.017 · Cited by 185 · see citing works
Frank, P., Jokela, M. M., Batty, G. D., Cadar, D., Steptoe, A., & Mika Kivimaki, B. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.20121776 · Cited by 184 · see citing works
Baumeister, D., Ciufolini, S., & Mondelli, V. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4044-5 · Cited by 183 · see citing works
Abautret-Daly, Á., Dempsey, E., Parra‐Blanco, A., Medina, C., & Harkin, A. (2017) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.3 · Cited by 185 · see citing works
Rosenblat, J. D., & McIntyre, R. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.042 · Cited by 179 · see citing works
Dooley, L. N., Kuhlman, K. R., Robles, T. F., Eisenberger, N. I., Craske, M. G., & Bower, J. E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.006 · Cited by 176 · see citing works
The role of the immune system in posttraumatic stress disorder
Katrinli, Ş., Oliveira, N. C. D. S., Felger, J. C., Michopoulos, V., & Smith, A. K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02094-7 · Cited by 177 · see citing works
The microbiota, immunoregulation, and mental health: implications for public health
Lowry, C. A., Smith, D. G., Siebler, P. H., Schmidt, D., Stamper, C. E., Hassell, J. E., Yamashita, P. S., Fox, J. H., Reber, S. O., Brenner, L. A., et al. (2016) · Current Environmental Health Reports · doi:10.1007/s40572-016-0100-5 · Cited by 172 · see citing works
Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.036 · Cited by 174 · see citing works
Davis, M. T., Holmes, S. E., Pietrzak, R. H., & Esterlis, I. (2017) · Chronic Stress · doi:10.1177/2470547017710916 · Cited by 176 · see citing works
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171 · see citing works
Fancourt, D. E., Perkins, R., Ascenso, S., de Carvalho, L. A., Steptoe, A., & Williamon, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151136 · Cited by 170 · see citing works
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171 · see citing works
Klawonn, A. M., Fritz, M., Castany, S., Pignatelli, M., Canal, C., Similä, F., Tejeda, H. A., Levinsson, J., Jaarola, M., Jakobsson, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2020.12.016 · Cited by 161 · see citing works
Ren, Q., Ma, M., Ishima, T., Morisseau, C. H. P., Yang, J., Wagner, K. M., Zhang, J.-C., Yang, C., Yao, W., Dong, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601532113 · Cited by 161 · see citing works
Zhang, J., Xie, X., Tang, M., Zhang, J., Zhang, B., Zhao, Q., Han, Y., Yan, W., Peng, C., & You, Z. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.012 · Cited by 150 · see citing works
Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A. S. H., de Haan, L., & van Beveren, N. J. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.039 · Cited by 161 · see citing works
Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder
Mahajan, G., Vallender, E. J., Garrett, M. R., Challagundla, L., Overholser, J. C., Jurjus, G., Dieter, L., Syed, M., Romero, D. G., Benghuzzi, H., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.017 · Cited by 159 · see citing works
Wang, J., Zhang, Y., Chen, Y., Wang, Y., Li, S., Wang, Y., ZHANG, Z.-X., Zhang, J., & Rong, P. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02341-6 · Cited by 158 · see citing works
Kim, Y., & Won, E. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.020 · Cited by 157 · see citing works
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156 · see citing works
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · see citing works
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 119 · see citing works
Haroon, E., & Miller, A. H. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_40 · Cited by 153 · see citing works
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
